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Background: von Willebrand disease (VWD) is the most common autosomal bleeding disorder, mostly 
inherited as dominant trait. VWD is due to deficiency/abnormality of von Willebrand factor (VWF). The 
true prevalence of VWD is unknown, but estimated as 0.1% to 1% of the general population. 
Methods: The bleeding score (BS) was used to evaluate the bleeding status of patients presenting at 
our institution. Laboratory analyses include: VWF:Ag, VWF:RCo, VWF:CB, multimeric pattern, VWF 
propeptide, Desmopressin challenge test. Genotypic analysis comprises the study of specific exons of VWF, 
depending on the suspected variant.
Results: We describe the main characteristics of our VWD population, including phenotypic and 
genotypic methods used to achieve the diagnosis. From our 2,482 patients registered, quantitative variants 
account for 83.2% of cases, and qualitative, 16.8% of cases. Platelet-type VWD (PT-VWD) was diagnosed 
in two patients and acquired von Willebrand syndrome (AVWS) in six. From quantitative variants, relative 
frequencies are: possible type 1, 78.7%; type 1, 14.9%; type 1S, 1.5%; type 1C, 0.4%; type 3, 1.6%. From 
qualitative variants: 2M, 21.9%; 2B, 10.3%; 2A, 8.4%; 2N, 3.4%; patients currently without complete 
diagnosis: 56%. Family history of bleeding: 64.7% of cases. Type 3, 2A and 2B VWD showed the highest 
major bleeding (MB) frequency. Genotypic diagnosis was reached in eight type 1C, 72 type 2M, 38 type 
2B, 30 type 2A, 14 type 2N, and two PT-VWD patients. Five de novo mutations were identified among 
52 families (9.61%): two mutations were associated with type 2B VWD (p.V1316M and p.S1310F), one 
mutation associated with type 1C (Vicenza) (p.R1205H) described in combination with p.R924Q, one 
deletion associated to type 1 VWD according to the ISTH VWF database (p.Pro1648fs*45) in combination 
with p.R1426C resulting in a 2M phenotype and one mutation related to type 2A VWD (p.Y1542D). Six 
patients are under prophylactic treatment due to their severe bleeding: four are type 3 VWD, one type 2M 
VWD, and one, the patient with p.Pro1648fs*45 and p.R1426C.
Conclusions: The wide heterogeneity of clinical symptoms and laboratory data from possible type 1 
VWD implies a risk for bleeding that becomes crucial in challenging situations. In our population, type 2M 
was found to be more frequent than the type 2A variant. DDAVP (1-deamino-8-D-arginine vasopressin) 
challenge test, VWF propeptide/antigen ratio and genotypic studies are useful tools for discriminating 
cases representing difficult diagnoses such as type 2M versus type 1C VWD. Elevated propeptide ratio, 
the detection of antiphospholipid antibodies, platelet-associated antibodies or anti-VWF immunoglobulins 
and negative genotypic screening is useful to discriminate inherited VWD from AVWS. Genotypic testing 
assisted discrimination between types 2B versus platelet-type-VWD and type 2N VWD versus mild 
hemophilia A.
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Introduction
von Willebrand disease (VWD) is the most common 
inherited bleeding disorder, affecting 0.1% to 1% of 
the total population (1,2), although the prevalence of 
symptomatic patients is closer to 0.01% (1). However, 
the true prevalence of VWD is unknown, and difficult to 
determine (3). Since the early eighties, our institution has 
been studying patients referred to us because of personal 
and/or family bleeding histories or abnormal pre-surgery 
hemostasis assays. Since then, we have established a 
reference center for VWD diagnosis, laboratory testing, 
and treatment in Argentina, with growing experience over 
the last four decades. During these years, we have improved 
our evaluation of patients through the incorporation of 
additional discriminating assays, including RIPA mixing 
tests and cryoprecipitate challenge for the differential 
diagnosis between platelet-type VWD (PT-VWD) and type 
2B VWD, and the genotyping study of GP1BA.
In recent years, considerable advances have been made 
world-wide regarding the diagnosis of VWD, and including:
(I) the age-related increase of von Willebrand factor 
(VWF) levels in type 1 VWD patients may result 
in a normalization of hemostatic parameters and 
sometimes bleeding symptoms, thereby potentially 
also changing a patient’s ‘diagnosis’ (4); this finding 
has only been confirmed in the ‘mild’ VWD 
subgroup, with less definitive changes seen in the 
definite type 1 VWD subgroup (5). Increasing 
bleeding score (BS) in type 1 VWD (6) but no 
change in VWF and FVIII levels with an increased 
bleeding risk in type 2 VWD with aging was 
described (7). However, it has less extensively been 
explored as to whether the hemorrhagic phenotype 
improves with aging (8).
(II) findings related to the involvement of different 
polymorphisms on VWF:Ag levels among different 
ethnic and racial groups (9,10). This makes 
necessary the better characterization of ethnic and 
racial variations in VWF, otherwise resulting in 
ambiguity or erroneous conclusions that might 
have an impact on the diagnosis of VWD; 
(III) the development of new methods to measure 
VWF activity (11), including: (i) VWF:GPIbR: 
based on the ristocetin-induced binding of VWF 
to a recombinant wild-type GPIb fragment (12); 
(ii) VWF:GPIbM: based on the spontaneous 
binding of VWF to a gain-of-function variant 
GPIb fragment (13); (iii) VWF:Ab: based on the 
binding of a monoclonal antibody to a VWF A1 
domain epitope (12); (iv) VWF:2b3aB: to measure 
VWF binding to αIIb β3 (14); (v) the use of type 
IV and VI collagen for VWF:CB assay (15); (vi) the 
development of automated methods for VWF:CB 
assay (16);
(IV) the development of new methods for molecular 
genetic testing approaches that include the 
use of a multi-gene panel, and next-generation 
sequencing (12); 
(V) the last approach of ISTH-bleeding assessment 
tool (ISTH-BAT), the semi quantitative system to 
measure the amount of clinical bleeding, named 
BS, applied to VWD patients (17,18); 
(VI) the description of pathogenic variants, which have 
been identified in 60–65% of individuals with type 
1 VWD (19,20). 
Our aim in this paper is to show the phenotypic and 
genotypic characteristics of the VWD population assessed 
by our institution. Genetic testing was unfortunately only 
performed in a minority of our patients, given the high cost 
of these studies. We have therefore focused genetic testing 
for type 2 VWD patients.
Criteria and strategy for diagnosis 
The rational diagnostic strategy for VWD patients is based 
on phenotypic analysis and, in specific cases, additionally 
on genotypic analysis. All patients undergo a minimum of 
two separate laboratory studies. As usual in clinical practice, 
the most abnormal value for any given test is considered for 
the final diagnosis. Possible associations between VWD and 
other disorders, such as hemophilia A, and B, and different 
Keywords: Desmopressin; hemorrhage; mutations; von Willebrand disease (VWD); von Willebrand factor (VWF)
Received: 27 November 2017; Accepted: 07 December 2017
doi: 10.21037/aob.2017.12.04
View this article at: http://dx.doi.org/10.21037/aob.2017.12.04
Annals of Blood, 2017 Page 3 of 14
© Annals of Blood. All rights reserved. Ann Blood 2017aob.amegroups.com
thrombopathies should also be considered (21). Previously, 
the BS was calculated according to the “Vicenza” BS; 
subsequently, it has been changed to the ISTH- BAT (17), 
being defined as normal if 0–3 in adult males, 0–5 in adult 
females, and 0–2 in both male and female children (18).
Major bleeding (MB) is defined as per Schulman 
et al .  (22),  and includes transfusion requirements 
[recombinant or blood derivatives infusion, DDAVP 
(1-deamino-8-D-arginine vasopressin) or antifibrinolytic 
agents], need of hospitalization, surgical re-intervention, or 
any other urgent procedures or decisions. 
Types 1 and 3 variants of VWD
It is relatively easy to distinguish type 1 from type 3 VWD 
by its milder bleeding tendency and VWF deficiency. 
Differentiation of type 1 and possible type 1 requires more 
effort, given the incomplete penetrance of the phenotype, 
the variable expression of bleeding symptoms, and 
difficulties in standardizing diagnostic tests (23). Subjects 
with low VWF (31–50 IU/dL) and mild bleeding symptoms 
may be considered as “low VWF” (24) or “possible” 
type 1 VWD (25). In these cases, family history may be 
negative (12). To be considered as having type 1 VWD, 
the subject should have VWF:RCo below the blood group 
specific normal range, bleeding symptoms (26) and a family 
history or a causative mutation. Notably, variations in the 
VWF sequence have been described in only 44% of type 1 
patients with VWF:Ag levels ≥30 IU/dL (3). 
Changes in VWF:Ag and VWF:RCo levels according 
to aging have been described, with an increase of 0.17 and 
0.15 IU/mL per decade (4) in the normal population. It 
is also known that individual with blood O group have 
VWF levels around 25% lower than those of non-O group, 
probably resulting from differences in glycosylation that 
may alter VWF clearance rates (27). The difference is 
more pronounced in elderly individuals, where the VWF 
increases only 1.25-fold in O-group, against 1.71-fold 
increase in non-O group (27). This consideration may be 
particularly important in type 1 VWD.
Our criteria for diagnosing quantitative disorders of 
VWD are: possible type 1: VWF:RCo within 31–49 IU/dL, 
type 1 VWD with a VWF:RCo within 15–30 IU/dL, and 
severe type 1 (type 1S) with VWF:RCo within 5–15 IU/dL, 
and with a poor response to DDAVP. Type 1C comprises 
those cases in which VWF shows a shortened survival after 
DDAVP challenge test and high VWFpp ratio (28).In all 
these cases, VWF:RCo/VWF:Ag (RCo/Ag) are ≥0.6. Type 
3 are those patients with VWF <5 IU/dL, FVIII:C usually 
<10 IU/dL. The use of DDAVP in type 3 VWD patients is 
known to be ineffective. 
Type 2 variants of VWD
Type 2 VWD is characterized by an impaired VWF 
function, towards platelets or FVIII (29). Type 2A, 2B 
and 2M VWD is intially identified by RCo/Ag <0.6, with 
normal or slightly reduced levels of VWF:Ag and FVIII:C. 
In type 2N, the deficiency of VWF resides in the binding 
of FVIII:C to VWF; type 2N VWD is suspected when 
FVIII:C is very low, the FVIII:C/VWF:Ag is <0.7 and 
furthermore suggested when the FVIII-VWF binding assay 
(VWF:FVIIIB/VWF:Ag) is <0.8, with normal VWF. Until 
we find a candidate mutation, however, we refer to these 
cases as “probable VWD2N”. 
Type 2A and 2M show low affinity of VWF for GPIb, 
reduced or absent RIPA at 1.2 mg/mL ristocetin, with 
normal multimers in type 2M. Type 2B shows a gain of 
function of VWF for GPIb and subsequently enhanced 
RIPA at low doses (<0.8 mg/mL), with absence of large 
multimers of VWF. The platelet count may range from low 
to normal (30). In situations of stress, such as pregnancy 
or response to DDAVP, thrombocytopenia is accentuated. 
An atypical form of type 2B has also been described, 
characterized by normal platelet count, normal multimers, 
and normal RCo/Ag (31). A proposal has been made to 
distinguish these as type 2B-I, being those patients lacking 
in large multimers, versus type 2B-II, being those with 
normal multimeric profile, with or without a normal 
VWF synthesis, in order to better classify type 2B VWD 
patients (32). PT-VWD is a very rare bleeding disorder, 
caused by the presence of mutations in GP1BA, which result 
in a platelet function defect, evidenced by an increased 
affinity of platelets for VWF. Seven mutations in the GP1BA 
gene related to PT-VWD have so far been described, and 
about 50 patients are currently reported world-wide (http://
pt-vwd.org/. Accessed: November 2017). One of these 
mutations has been newly described by us (33). Herein, 
VWF is not involved per se. However, because PT-VWD 
patients show similar bleeding symptoms and laboratory 
abnormalities as type 2B VWD, their study is typically 
included in VWD reviews. The differential diagnosis 
between the two entities is especially challenging, as 
evidenced by high levels of misdiagnosis of both conditions, 
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but particularly PT-VWD, which has been reported as 
type 2B VWD in ~15% of cases (34). Both PT-VWD 
and type 2BVWD may also be misdiagnosed as idiopathic 
thrombocytopenia (34). For this reason, the real PT-VWD 
incidence is unknown (34). The therapeutic management 
of the two disorders is different, so that discrimination is 
clinically essential.
Methods
Sample preparation
Peripheral venous blood is drawn in 3.13% sodium 
citrate for clott ing tests ,  in 2% EDTA for DNA 
analysis, and with anti-proteases (2.8% sodium citrate; 
60 mM N-ethylmaleimide, 50 mM EDTA (disodium 
ethylenediaminetetraacetate dihydrate), and 2,000 KIU/mL 
aprotinin) for multimeric profile. Laboratory investigation 
is offered to all available members of affected families.
Phenotypic analysis
The following tests are performed: complete blood count 
that includes platelet count (Plt); bleeding time (BT) 
[Ivy method, normal value (nv) ≤4.5 min]; factor VIII 
(FVIII:C) (35) [one-stage method, normal range (nr): 50-
150 IU/dL]; VWF antigen (VWF:Ag) (36) (ELISA, nr: 
50–150 IU/dL); VWF ristocetin cofactor (VWF:RCo) (37) 
(aggregometry, nr: 50–150 IU/dL); VWF collagen binding 
(VWF:CB) (ELISA, collagen type 1, nr: 60–130 IU/dL); 
VWF FVIII binding (VWF:FVIIIB), VWF propeptide 
(VWFpp) (38) (ELISA); VWF multimeric analysis (39), 
using SDS 1% and 1.7% agarose gel electrophoresis. FVIII/
VWF:Ag (nv ≥0.7), VWF:RCo/VWF:Ag (RCo/Ag) (nv 
≥0.6), VWF:CB/VWF:Ag (CB/Ag) (nv ≥0.6), and VWFpp/
VWF:Ag (VWFpp ratio) (nr: 0.92–2.14) are calculated. The 
presence of anti-VWF antibodies in patients with either 
prolonged activated partial thromboplastin time (APTT) 
or VWF:RCo <10 IU/dL or with clinical suspicion of 
acquired von Willebrand syndrome (AVWS) is performed 
as previously described (40); however, antibodies to 
nonfunctional domain will be missed on such functional 
testing. We therefore developed an ELISA technique to 
detect anti-VWF antibodies as previously described (41), 
but with some modifications. Ristocetin induced platelet 
aggregation (RIPA) at 1.2 mg ristocetin/mL is the first 
RIPA test performed. Where RIPA 1.2 mg/mL is normal, 
testing is repeated using ristocetin 0.5–0.7 mg/mL, looking 
for the threshold ristocetin concentration; where RIPA 
1.2 mg/mL is absent, testing is repeated using ristocetin 
at 1.5 and if  required 2 mg/mL (http://www. isth.
org/?page=ssc_minutes/; 56th SSC meeting of ISTH 2010. 
Accessed: November 2017).
When PT-VWD is suspected, discriminating methods 
(RIPA mixing assay and cryoprecipitate challenge assay) are 
performed as previously described (42,43).
Not all these tests are routinely performed on all 
patients. VWF:CB, multimeric analysis, and VWFpp are 
performed in selected patients, according to the results of 
previous phenotypic studies. A local plasma-pool obtained 
from 20 healthy donors is used as a secondary standard 
calibrated against the standard 07/316 of the National 
Institute of Biological Standards and Control (NIBSC).
As described before (3), given our lower limit of 
detection for VWF:RCo is 10 IU/dL, levels <10 IU/dL 
were taken as 5 IU/dL for calculation of means and ratios.
Genotypic analysis
There are several situations in which differential diagnosis 
in VWD is mandatory: between hereditary congenital and 
AVWS (44), between type 2N VWD and mild hemophilia 
A (45) and between type 2BVWD and PT-VWD (42). In 
all these situations, the definitive diagnosis remains the 
identification of mutations. 
Genetic testing for VWD is not performed routinely. 
Since 1998, we have performed genotypic studies in patients 
with suspected type 2N, and subsequently in patients with 
suspected 2A, 2M, 2B, and PT-VWD. Genomic DNA is 
extracted from peripheral blood using standard methods. 
Exons of interest are amplified using polymerase chain 
reaction (PCR) technique. In probable type 2N VWD 
patients, exons 17 to 27 of VWF gene are analyzed. In 
type 2A, 2M and 2B patients, given the high frequency of 
mutations located in the exon 28, we start genotypic studies 
through the analysis of this exon (46). Subsequently, where 
no mutations are found, exons 26, 27, 29, 30, 31 and 52 
are also analyzed. When PT-VWD is suspected, GPIBA is 
analyzed. Primers for PCR were designed in our laboratory. 
Both forward and reverse strands are directly sequenced by 
automated sequencing technology (ABI Prism 310 Genetic 
Analyzer; Applied Biosystems, Foster City, CA, USA). 
When mutations are found in the index cases, genotypic 
studies are offered to all available relatives to confirm 
familial transmission.
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Figure 1 shows an algorithm that describes the VWD 
diagnostic strategy.
Biologic response to desmopressin
DDAVP is a synthetic analog of the vasopressin, which 
increases two to five times the basal level of circulating 
FVIII/VWF within 30–60 min and last by 6–8 hours post 
infusion, returning to basal levels after 24 hours (47). This 
effect is achieved by the FVIII/VWF releases from storage. 
In cases of increased clearance, levels return to base-line 
after 1–4 hours. DDAVP does not normally show significant 
side effects and it is safe from the risk of transmitting blood 
viruses. It is generally contraindicated in type 2B VWD 
because of the transient appearance or aggravation of 
thrombocytopenia (30). However, DDAVP was described 
as appropriate in type 2B VWD patients with normal 
multimeric pattern and platelet count (32). Because of its 
antidiuretic properties, such as hyponatremia, and volume 
overload, it should be used with caution in elderly subjects 
with cardiovascular or atherosclerosis disease (25), and in 
children below the age of 2 years (25).
In our institute, DDAVP is infused intravenously 
(0.3 µg/kg body weight during 20 min in 50 mL saline 
solution). Blood samples are obtained before, 60 and 
120 min after the end of the infusion. In case of children 
below 20kg of body weight, samples are obtained before 
and 90 min after (48). In accordance with the National 
Heart, Lung and Blood Institute guidelines on VWD (25) 
we do not use DDAVP in children <2 years of age. The 
time courses of Plt, BT, FVIII:C, VWF:Ag, VWF:RCo 
and euglobulin clot lysis time are analyzed. A good 
response is considered when all abnormal parameters reach 
normal levels. A poor response is when FVIII, VWF:Ag 
or VWF:RCo do not reach normal levels or when these 
levels fall rapidly (i.e., within 2 h) after the infusion. No 
response means that all the parameters remain abnormal, or 
in type 2N VWD patients, where FVIII:C does not reach 
plasma levels required for hemostasis (≥50 IU/dL) (49). In 
these cases of accelerated fibrinolytic response, the dose of 
DDAVP is reduced to 0.2 µg/kg body weight, for further 
treatments. The success of the test depends on the infusion 
time, which must be strictly observed and the time between 
the end of the infusion and the start of the bleeding event to 
Figure 1 The algorithm of VWD diagnostic strategy. VWF, von Willebrand factor; VWD, von Willebrand disease; RIPA, ristocetin-
induced platelet aggregation; HMWM, high molecular weight multimers; IMWM, intermediate molecular weight multimers. 
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be prevented. 
Minor local bleeding (nasal or oral bleeding) may be 
managed with topical hemostatic agents or local pressure 
for long time. The most common topical agents are: fibrin 
sealants, topical thrombin, micronized collagen strips (25).
The most frequent pharmacologic agents are: fibrinolysis 
inhibitors such as aminocaproic acid, and tranexamic acid, 
which are very frequently used in dental procedures and 
menorrhagia (50), and hormonal treatments with estrogen-
progesterone combined oral contraceptives that are useful 
in treatment of menorrhagia (25).
In silico evaluation
In silico evaluation is being used more and more frequently 
by several groups to predict effects of nucleotidic changes 
on the integrity of the resulting protein. In our laboratory, 
the in silico analysis was performed using PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/. Accessed: November 
2017), Panther (http://pantherdb.org/ Accessed: November 
2017), and Mutation Taster (http://www.mutationtaster.
org/. Accessed: November 2017). The sequence alignment 
of the proteins is performed using the informatics 
application UniProt KB (www.uniprot.org. Accessed: 
November 2017). 
Results
Characteristics of our VWD population
Our country has nearly 44 million inhabitants. From 
1982 to December 2016, a total of 5,439 patients were 
studied at our institution and the final VWD diagnosis was 
reached in 2,482 patients. We do not have an estimation 
of prevalence of VWD in our country, because this is a 
report from a single institution. A total of 83.2% of patients 
were diagnosed as having a quantitative VWD, whereas 
16.8% were type 2 VWD. Two patients were diagnosed 
as PT-VWD and six patients as AVWS. The true global 
prevalence of the different VWD variants is unknown, but 
type 1 VWD is believed to represent 65–80% of all the 
VWD population (51). The prevalence of type 1 VWD 
variants in our population is quite similar to those of other 
Table 1 Classification of our VWD patients, according to their phenotype
Type of VWD Overall, n (%) Females (%) Blood O group (%) ≤13 years-old (%) With family history (%) With MB (%)
Quantitative variants, n=2,066 (83.2%)
Possible type 1 1,626 (78.7) 70 76.1 24 61.6 12.8
Type 1 308 (14.9) 66.4 83.3 24 67.8 15.2
Type 1S 30 (1.5) 54.8 72,2 41.9 66.6 33.3
Type 1C 8 (0.4) 62.5 50 20 100 40
1+probable 2N 60 (2.9) 13.9 74.2 46.8 60.8 60.2
Type 3 34 (1.6) 55.8 73.6 41.2 82.1 62
Qualitative variants, n=416 (16.8%)
Probable 2N 31 (7.5) 37.6 53.5 17 80.5 18
2N 14 (3.4) 2.4 50 28.5 90 30
2A 35 (8.4) 55.5 37.5 25 93.1 60
2B 43 (10.3) 53.4 70.5 25.6 84.6 60.4
2M 91 (21.9) 56.1 62.3 39.3 88.4 38.4
2 unclassified 202 (48.6) 54.5 64.4 30.5 54.8 20.6
AVWS 6 40 50 0 0 100
PT-VWD 2 0 50 0 50 100
Number and percentage of patients within their variant group. VWD, von Willebrand disease; MB, major bleeding; AVWS, acquired von 
Willebrand 
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reports (Table 1). Seventy-five percentage of patients were 
under 13 years of age at enrollment; the more severe VWD, 
the younger the patients. Blood O group was shown in 74% 
of all patients. The highest frequency of this blood group 
was observed in type 1 (83.1%), possible type 1 (76.1%), 
and type 2B (70.5%), whereas in our normal population 
is near 50% (52). Only 64.7% of the patients have family 
history of bleeding. The prevalence of females was 60.7%, 
especially in type 1 VWD. In patients with type probable 
2N and combined type 1+probable 2N, the frequency of 
males is higher than females (P<0.0001). 
Although 0.29% of parental consanguinity rate in 
normal births were reported in our country, we have one 
case of recognized parental consanguinity in one 2-year girl 
with type 3 VWD whose parents (brother and sister) were 
diagnosed as type 1 VWD.
Quantitative subtypes
Phenotypic analysis
Within our patients belonging to quantitative variants, 
possible type 1 is the most frequent. Type 3 accounts for 
only 1.6%, and type 1C that includes type Vicenza, for 
0.4%. The laboratory data of the quantitative variants are 
summarized in Table 2.
The most frequent bleeding symptoms seen in 
quantitative variants were bleeding after tooth extraction, 
bleeding related to surgery, epistaxis, bleeding related 
to parturition/delivery, and in females of fertile age, 
menorrhagia. Joint bleeding was reported in 0.77% of 
patients (14.7% of type 3 VWD patients). Overall, lower 
levels of VWF:RCo, a higher percentage of patients with 
bleeding symptoms, especially epistaxis and bleeding, 
related to surgeries.
The median of age at the enrollment in possible type 
1 was 22 years (range: 1–73 years), and in type 1 patients 
23 years (range: 1–67 years), both variants with 24% of 
patients below 13 years old. In these cases, it is important 
to consider that at that age of diagnosis, patients have had 
less time to accumulate bleeding symptoms, as highlighted 
previously (3). This is the case for possible type 1 VWD 
patients, who show a wide heterogeneity not only in their 
BS, but also in their MB incidence. Unexpectedly for 
their VWF levels, BS ≥10 was observed in 2% of patients, 
quite similar to that observed in type 1 (5% of patients). 
MB incidence was 12.8% in possible type 1 VWD, 
versus 15.2%in type 1 VWD (P=0.01; RR, 1.19; 95% CI: 
0.89–1.60). On the other hand, 10.2% of possible type 1 
VWD patients do not have personal bleeding symptoms, 
quite similar to type 1 patients (9.5%) (P=ns), with no 
difference in the frequency of blood O group (P=ns). In 
addition, normal levels of FVIII are found in 44% of type 
1 and possible type 1 variants. Then, considering all these 
findings and the variability in FVIII and VWF over time, 
the differences between the possible types 1 and type 1 are 
subtle. Asymptomatic patients with low values of VWF 
should be regarded with caution, as many of them might 
not have had a hemostatic challenge to manifest a bleeding 
tendency. This implies a risk for bleeding that acquires an 
important value in challenging situations, such as surgeries. 
Recently a non-significant difference in BS between 
blood O group and non-O blood group was described in 
type 1 VWD patients, with no correlation with VWF:Ag (3). 
In agreement with the authors, in our cohort, when possible 
Table 2 Laboratory data of quantitative variants
VWD BS VWF:Ag, IU/dL FVIII:C, U/dL FVIII/Ag VWF:RCo, IU/dL RCo/Ag BT, min VWFpp ratio
Possible type 1 3.5±2.4 43.5±11.7 51±19 1.18±0.3 41.6±5.3 1.2±0.6 4.8±1.8 ND
Type 1 4.2±2.8 35±11.6 50.6±30.3 1.4±0.5 25.8±4.2 0.9±0.3 5.2±2.6 ND
Type 1S 5.7±3.2 14.8±8.6 38±11.8 2.7±0.4 7.9±6.0 NA 6.2±2.7 1.5±0.2
Type 1C 4.7±2 14.1±5.8 35.6±13.1 2.5±0.9 10.9±5.3 0.9±0.2 5.8±2.4 5.3±3.5
Type 1 probable 2N 6.4±3.1 43±9.6 9.7±8.5 0.22±0.1 40.2±7 1±0.25 4.6±1.7 ND
Type 3 9±4.8 1.7±1.9 12.4±8.9 7.3±1.5 1±0 NA 11.8±2.9 ND
VWD, von Willebrand disease; BS, bleeding score; FVIII:C, factor VIII; VWF:Ag, von Willebrand antigen; VWF:RCo, ristocetin cofactor 
activity; RCo/Ag, ristocetin cofactor activity/antigen ratio; BT, bleeding time; VWFpp ratio, propeptide/antigen ratio. NA, not applicant; ND, 
not done.
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type 1 and type 1 VWD patients were grouped according 
to their BS and blood group, no correlation was observed 
between FVIII:C, VWF:Ag, VWF:RCo and BT between 
blood O group and non-O group (Table 3). In addition, no 
difference was observed in the percentage of patients with 
similar BS between blood O group and non-O group.
Individuals with both low VWF and FVIII/VWF:Ag 
<0.7 resulted in a more severe bleeding phenotype: patients 
with type 1+ probable 2N showed higher frequency of MB 
(P<0.0001; RR, 3.37, 95% CI, 2.42–4.68) than probable 
2N. The same finding was observed when we compared 
type 1+ probable 2N versus possible type 1 (P=0.0001; RR, 
4.71; 95% CI, 3.78–5.87).
Regarding type 3 VWD, the median age of enrollment 
was 16 years (range: 1–61years), with 41.2% of patients below 
13 years and 29.4% ≥40 years. Joint bleeding was reported in 
14.7% of patients. Four patients (11.7%) within seven months 
to 6 years of age are currently under long-term prophylactic 
treatment because of the severity of their bleeding episodes.
Genotypic analysis
Eight cases of type 1C VWD have been identified: 
two patients with type Vicenza: one of them, with 
heterozygous p.R1205H, and the other patient, with 
combined heterozygous p.R1205H and p.R924Q (53). 
In the remaining six patients, p.R1315C was identified in 
heterozygous state. 
Qualitative subtypes
Phenotypic analysis
It has been described that type 2M VWD is more often 
misidentified than correctly identified as 2M VWD (47), 
giving an under-reported incidence of this variant in the 
literature. In our patients belonging to qualitative variants, 
type 2M was the most frequent, followed by type 2B, 
and type 2A, and type 2N. In 56% of patients overall, 
the subtype could not be identified because the necessary 
additional phenotypic and genotypic studies could not be 
performed.
The most frequent symptoms were bleeding after tooth 
extraction, bleeding related to surgery, menorrhagia, 
hematomas, and epistaxis. Joint bleeding was reported 
in 8.6% of patients (5.7% of type 2A VWD patients). 
The qualitative group showed higher bleeding tendency 
than the quantitative group (P=0.000; RR, 1.57; 95% 
CI, 1.33–1.87). Type 2B VWD was the group with the 
highest MB frequency (60.4%), followed by type 2A (60%), 
2M (38.4%), type 2N (30%), and probably 2N (18%) 
(Table 1). Type 2A patients showed a significant higher 
bleeding tendency than type 2M patients (P=0.025; RR, 
1.67; 95% CI 1.13–2.46), but not significantly higher than 
those of type 2B patients. However, a 3-year-old girl with 
type 2M VWD is currently under long-term prophylactic 
treatment.
The laboratory data are summarized in Table 4.
Table 3 Comparison between different ranges of BS versus blood group and laboratory tests in possible type 1 and type 1 VWD patients 
VWD Laboratory tests
Blood group (O group/non-O group)
BS ≥10 BS from normal to 9 Normal BS
Type 1 % of patients 7.3/4* 40.2/24* 52.5/72*
FVIII:C, IU/dL 60±28/20 48±17/62±36* 49±18/54±21*
VWF:Ag, IU/dL 31±6.9/20 32±11/41±14* 34±11/35±17*
VWF:RCo, IU/dL 25±4.5/25 26±4/28±3* 27±4/24±4*
BT, min 6±2.5/– 5±2/3±1* 5±2/5±2*
Possible type 1 % of patients 2.6/2.3* 27.3/21* 70/76.7*
FVIII:C, IU/dL 44.2±18/63±27* 51±18/52±25* 50±17/53±22*
VWF:Ag, IU/dL 42.6±8/47±4.7* 42±9/43±10* 42±11/45±12*
VWF:RCo, IU/dL 41.2±8/43±6.2* 41±5/43±6* 42±5/42±5*
BT, min 4.9±2.2/6±1.7* 5±2/5±2* 5±2/5±2*
VWD, von Willebrand disease; BS, bleeding score; FVIII:C, factor VIII; VWF:Ag, von Willebrand antigen; VWF:RCo, ristocetin cofactor 
activity; BT, bleeding time; *, not significant.
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Genotypic analysis
From the 416 patients with qualitative phenotype, 
responsible mutations were identified in 156 patients 
(37.5%). 
Patients with type 2A VWD
From our total of 35 type 2A patients, the exon 28 was 
sequenced in 33 individuals. Six mutations were identified 
in heterozygosis in 30 patients: p.C1272F (n=2), p.G1505R 
(n=3), p.Y1542D (n=1), p.R1597W (n=16), p.I1628T (n=6) 
and p.F1654L (n=2). In three patients, no mutations were 
observed in this exon. The p.R1597W, located in the A2 
domain, was the most frequent mutation in this variant.
Patients with type 2B VWD
From our total of 43 type 2B patients, seven mutations in 
heterozygosis were identified in 38 patients: p.Y1258C 
(n=1), p.P1266L (n=1), p.M1304V (n=3), p.R1306W (n=8), 
p.R1308C (n=9), p.S1310F (n=4), and p.V1316M (n=12).
Two mutations, p.P1266L and p.M1304V were associated 
with atypical type 2B VWD, given the presence of normal 
HMWM and platelet count (54), according to Casonato’s 
description (31). The p.V1316M was the most frequent 
mutation in this variant.
Patients with type 2M VWD
Eighty out of 89 type 2M VWD patients were available 
for sequencing of exon 28; 14 mutations were identified in 
74 patients: in heterozygosis: p.F1293C (n=2), p.R1315C 
(n=2), p.G1324S (n=1), p.S1325F (n=1), p.R1334Q (n=1), 
p.R1374C (n=18), p.R1374L (n=1), p.A1437T (n=5), 
p.T1468I (n=1), p.L1503P (n=2), p.E1549K (n=32), 
p.R1564W (n=1), p.R1583W (n=1), and p.I1628T (n=4); 
and in homozygosis: p.R1374C (n=2; two sisters). In the 
remaining 6 patients, no mutations were observed in this 
exon. The p.E1549K was the most frequent mutation, 
observed in a big family (four generations) and in one 
unrelated individual. 
Patients with type probable 2N and type 1+probable 
2N VWD
We could genotypically study 215 patients with FVIII/
VWF:Ag <0.7. In this group, we found three mutations 
in heterozygosis in 14 patients: p.R854Q (n=6); p.R924Q 
(n=6), p.R816W (n=1), and a novel mutation p.D1195Y 
(n=1). Although type 2N VWD has been described as a 
recessive trait, in our case, all the patients had mutations 
in heterozygous state. No mutations were found in the T
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exons 17–27 of VWF gene in the remaining 201 patients. 
Given that 20% of patients with responsible mutations 
showed normal VWF:FVIIIB/VWF:Ag, this test was not 
performed anymore. These patients were referred to look 
for mutations related to hemophilia A.
Patients with PT-VWD
Two patients with phenotypic tests suggesting type 2B 
VWD were studied. Discriminating methods suggested 
PT-VWD diagnosis. Two mutations were found in GP1BA: 
p.W246L (33) in one patient, and p. M255V in the other 
patient. In these patients, no mutations were found in exon 
28 of VWF gene.
Patients with AVWS
Six patients with bleeding symptoms of late appearance 
showed phenotypic studies suggesting type 2 VWD. The 
absence of mutations to explain the phenotype helped 
the medical staff to redirect the studies over the search 
of AVWS. Elevated VWFpp ratio, the detection of 
antiphospholipid antibodies, platelet-associated antibodies 
or anti-VWD immunoglobulins (IgG, IgA or IgM) were 
common features among these patients. AVWS related to 
monoclonal gammopathy of undetermined significance was 
diagnosed in four patients, and related to antiphospholipid 
syndrome was diagnosed in the other two patients.
Discrepancies in genotype-phenotype relationships 
Diagnosis for VWD can also be complicated by incomplete 
penetrance and variable expressivity of the conditions 
described above. For example, ethnicity can influence the 
diversity seen in VWF. Some genomic variants of VWF are 
seemingly pathogenic in Caucasian populations, but benign 
in African individuals, which may contribute to an increase 
in the rate of false-positive diagnoses (10,55).
Discrepancies between the VWD variants and the 
candidate mutations related to different phenotypes have 
been reported in the ISTH-SSC VWF online database 
(http://www.ragtimedesign.com/vwf/. Accessed: November 
2017). This is the case of p.R1315C, which has been 
reported in association with type 2M (56), type unclassified, 
type 1 (57), type 2A (58), type 1C (59) and type 3. In our 
population, this mutation was found in nine patients with 
normal multimers, in whom the initial phenotype was not 
clear. These cases could be solved through VWFpp ratio 
and the DDAVP challenge test. In six patients, with high 
basal VWFpp ratio, very low VWF and RCo/Ag <0.6, the 
normalization of RCo/Ag but a rapid clearance of VWF 
after DDAVP infusion, suggested a type 1C phenotype; 
another two patients, with normal VWFpp ratio and 
discordant RCo/Ag before and after DDAVP infusion 
showed a type 2M phenotype, and other patient could not 
be differentiated as type 1C or 2M. 
We also found discrepancy in ten patients with p.I1628T; 
six patients showed a 2AVWD phenotype, whereas another 
four patients showed a 2M VWD phenotype. This mutation 
was reported in the ISTH-VWF database as type 2AVWD 
and polymorphism (SNP). Those patients with a 2A VWD 
phenotype showed significant longer BS than those with 
type 2M phenotype (P=0.03). These data show some 
diagnostic problems to be taken into account during patient 
investigations (46).
Another real challenge was the identification of two 
mutations with heterozygous and trans presentation in one 
of our patients with a type 2M VWD phenotype. The first 
mutation, p.R1426C, not previously described, responsible 
for probable type 1 in his mother, and the second mutation, 
the p.Pro1648fs*45, previously described associated with 
type 1VWD in the VWF SSC VWF database, which is 
absent in parents, suggesting a de novo presentation in the 
patient. The combined effect of both mutations resulted in 
a type 2M VWD, despite being individually associated to 
type 1 VWD (60).
De novo mutations
Occurrence of de novo mutations is a rare event in VWD 
families, although there are several cases described (61-64). 
Its frequency within families was reported as 14.3% (62), 
and 26.7% (61). In our cohort, five de novo mutations were 
identified among 52 families, with a frequency of 9.61%: 
two mutations associated with type 2B VWD (p.V1316M 
and p.S1310F) (54), one mutation associated with type 
1C (Vicenza) (p.R1205H), which has been described in 
combination with p.R924Q (53), one deletion associated 
to type 1 VWD according to the ISTH VWF database 
(p.Pro1648fs*45) and another mutation related to type 2A 
VWD (p.Y1542D). 
DDAVP challenge test
Results of DDAVP challenge tests in our VWD population 
are summarized in Table 5. The median age of patients at 
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the moment of testing was 18.4 (range: 3–55) years. From a 
total of 932 tests performed, 138 (14.8%) were <13 years.
Quantitative subtypes: over a total of 843 tests done, 
93% of patients showed a good response whereas 4.2% 
showed a partial response and 1.5% did not respond. A 
12.3% of patients were <13 years. Only one type 1 VWD 
patient was 3 years old. 
Qualitative subtypes: DDAVP response test was assessed 
in 89 patients. A total of 47.4% of these patients showed a 
good response, whereas 40.4% had a partial response, and 
12.2% did not respond. A 38.2% of patients were <13 years, 
especially in probable 2N VWD. Only five patients were 
between 2–4 years old.
DDAVP challenge test was very useful in identifying 
some patients with difficult interpretation of tests results, 
and the subsequent classification such as discriminating 
type 3 from severe type 1, and type 2M from type 1C when 
the VWF levels were inconclusive or too low. This was the 
case of two patients, who developed thrombocytopenia, 
and by this way, the diagnostic approach towards type 
2B VWD was addressed. Another similar case was our 
group of patients with the mutation p.R1315C, which was 
commented on previously.
Conclusions
The wide heterogeneity of clinical symptoms and laboratory 
data from possible type 1 implies a risk for bleeding that 
becomes crucial in challenging situations. 
In our population, type 2M VWD was found more 
frequent than type 2A variant.
Because of the absence of significant side effects in our 
patients, its effectiveness and low cost, DDAVP should be 
considered as the first-choice therapy in VWD, especially 
in developing countries.
DDAVP challenge test, VWF propeptide and genotypic 
studies were very useful tools for discriminating those 
cases with difficult diagnoses, such as type 2M versus 
type 1C VWD. Elevated VWFpp ratio, the detection of 
antiphospholipid antibodies, platelet-associated antibodies 
or anti-VWF immunoglobulins (IgG, IgA or IgM) and the 
negative genotypic screening were useful to discriminate 
inherited VWD from AVWS. Genotypic testing also helped 
us to discriminate between type 2B versus PT-VWD and 
type 2N VWD versus mild hemophilia A.
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